secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027706
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports Q4 net loss $19.2M; KOMET-001 trial hits primary endpoint; NDA plan Q2 2025
--------------------------------------------------------------------------------

- Q4 collaboration revenue $53.9M (from Kyowa Kirin), R&D $52.3M, net loss $19.2M vs $42.8M YoY.
- KOMET-001 achieved primary endpoint with 20-30% CR/CRh rate in R/R NPM1-mutant AML; NDA submission expected Q2 2025.
- FDA and EMA aligned on KOMET-017 Phase 3 protocol using MRD-negative CR for potential accelerated U.S. approval; topline 2028.
- Cash, equivalents and short-term investments $727.4M as of Dec 31, 2024; sufficient into 2027 with Kyowa funding.
- KOMET-007 Phase 1: 91% CR in 1L adverse-risk AML cohort with intensive chemo (7+3) combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/0000950170-25-027706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer